Research and Markets - Global Neuropathy Pain Treatment Market to Grow at a CAGR of 5.8%, 2017-2021 With Depomed, Eli Lilly, Endo International & Pfizer Dominating

DUBLIN, Mar 29, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Neuropathy Pain Treatment Market 2017-2021" report to their offering.

The global neuropathy pain treatment market to grow at a CAGR of 5.85% during the period 2017-2021.

The report, Global Neuropathy Pain Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in market is growing focus on emerging economies. The increasing focus of research institutes and vendors to tap the potential treatments in emerging economies will likely bring substantial growth opportunities. The increasing incidence of individuals with pain has fueled the demand in regions such as China, India, and Brazil. In addition, the research institutes have issued guidelines to address the unmet needs in the treatment of pain. For instance, a group of pain specialists from across APAC stated to have tailored guidelines for each region for the treatment of neuropathic pain. They also started to put greater effort to communicate about neuropathic pain treatments with general physicians. This will increase the accessibility of drugs in emerging and low- and middle-income regions of APAC. Vendors are also looking to tap the potential in emerging economies.

According to the report, one driver in market is presence of large patient pool. The presence of large patient pool with neuropathic pain is expected to fuel the market growth. Neuropathic pain is associated with various disorders such as diabetic neuropathy, chemotherapy-induced pain, shingles, and herniated disk. There has been growing cases of the population with these disorders. For instance, according to the CDC 2014 statistics, 29.1 million individuals in the US have diabetes in 2014. Out of this, around 6-7 individuals per 1,000 individuals are suffering from diabetic neuropathy. Also, the increasing individuals referring chemotherapy for cancer treatment is fueling the cases of chemotherapy-induced pain.

Key vendors

• Depomed
• Eli Lilly
• Endo International
• Pfizer
  

Other Prominent Vendors

• Allodynic Therapeutics
• Arbor Pharmaceuticals
• Astellas Pharma
• Aurobindo Pharma
• Avanir Pharmaceuticals
• Biogen
• Others
  

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview of neuropathic pain

PART 06: Market landscape

PART 07: Pipeline landscape

PART 08: Market segmentation by indication

PART 09: Market segmentation by drug class

PART 10: Geographical segmentation

PART 11: Decision framework

PART 12: Drivers and challenges

PART 13: Market trends

PART 14: Vendor landscape

PART 15: Key vendor analysis

PART 16: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/khs4sm/global_neuropathy

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716